HCPCS Level II J3397: Injection, vestronidase alfa-vjbk, 1 mg

HCPCS Level II code J3397 denotes the injectable biologic vestronidase alfa-vjbk, billed per 1 mg unit. This enzyme replacement therapy is used in specialized clinical settings and is billed as a drug administration line item under outpatient and ambulatory infusion services. Nationally, accurate use of J3397 affects reimbursement for high-cost specialty therapies and facility billing for infusion services.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage patterns, billing benchmarks, and common billing considerations for injectable biologics billed by unit. The publication also provides clinical context for vestronidase alfa-vjbk administration, typical sites of service, and where to expect differences in payer policies. Policy updates and coding guidance relevant to specialty injectable drugs are summarized to help billing and compliance teams understand common points of adjudication and documentation focus.

This summary is intended for a national audience of billing professionals, revenue cycle leaders, and clinical administrators seeking concise guidance on billing and payer considerations for J3397.

Billing Code Overview

HCPCS Level II code J3397 represents injection, vestronidase alfa-vjbk, 1 mg. This code is used for billing administration of vestronidase alfa-vjbk, an enzyme replacement therapy delivered by injection. The service type is an infusible or injectable biologic therapy. The typical site of service for this injection is an outpatient infusion center or hospital outpatient department, with administration also occurring in ambulatory clinics when clinically appropriate.

Data not available in the input.

Clinical Context

A pediatric or adult patient with confirmed mucopolysaccharidosis VII (Sly syndrome) presents for enzyme replacement therapy using vestronidase alfa-vjbk (J3397, 1 mg). The patient arrives to an infusion center or hospital outpatient infusion suite accompanied by a caregiver for baseline vitals and assessment. Prior to infusion, nursing documents weight, reviews recent labs (including liver function tests and renal function), confirms no recent febrile illness, and reviews pre-medication orders for hypersensitivity risk (e.g., antihistamine, corticosteroid, antipyretic) per the prescribing clinician.

The infusion is administered intravenously over the recommended infusion time with continuous nursing assessment for infusion-related reactions. Vital signs are recorded at baseline, periodically during the infusion, and after completion. If an infusion reaction occurs, the nurse follows the facility protocol which may include temporary infusion interruption, administration of rescue medications, and documentation of modifier(s) if applicable. Post-infusion, the patient is observed for a specified monitoring period and discharged with follow-up appointments for ongoing dosing cycles typically every two weeks as defined by the treatment plan.

Coding Specifications

Modifier	Description	When to Use
`JW`	Drug amount discarded/not administered	When partial vial waste occurs and discarded medication is reported per payer policy

Taxonomy Code	Specialty	Notes
`2085R0200X`	Pediatrician	Common treating clinician initiating and managing therapy for pediatric patients
`208000000X`	Internal Medicine	Adult management and oversight of enzyme replacement therapy
`363L00000X`	Hematology & Oncology	Specialists frequently coordinate complex biologic infusions and adverse event management
`3336C0002X`	Medical Geneticist	Diagnoses hereditary metabolic disorders and directs enzyme replacement therapy
`331600000X`	Allergy & Immunology	Manages infusion-related hypersensitivity and desensitization planning

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`E76.2`	Other mucopolysaccharidosis	Primary diagnostic category for patients receiving vestronidase alfa-vjbk for MPS VII
`E76.8`	Other specified sphingolipidosis and lipidosis	Related lysosomal storage disorder category considered when documenting differential diagnoses
`E75.0`	GM2 gangliosidosis	Example of another lysosomal storage disorder relevant in specialist documentation and differential
`R50.9`	Fever, unspecified	Relevant for documenting febrile events that may delay or modify infusion timing
`T88.7XXA`	Unspecified adverse effect of drug or medicament, initial encounter	Used if documenting an initial infusion-related adverse reaction needing further management

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	Commonly reported for the initial hour of therapeutic IV infusion when billing per infusion time
`96366`	Each additional hour (List separately in addition to code for primary infusion)	Used when infusion duration exceeds the first hour and additional hourly billing is supported
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	Used if a premedication is given as an injection separate from IV infusion
`36415`	Collection of venous blood by venipuncture	Performed for baseline and monitoring laboratory draws associated with treatment
`99214`	Established patient office visit, moderate complexity	May be used for pre-infusion or follow-up outpatient evaluation by the ordering clinician

OpenPayer

Summary & Overview